Actavis exec leaps to CEO job at rival Impax; Glaxo COPD med nabs Canadian approval; Jury slaps doc with $14M in damages in Yasmin case;

@FiercePharma: Top-read story over the long weekend: Gilead's Sovaldi, GSK's Anoro stand out in 2014's blockbuster crop, report says. Story | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. More from MediaPost | Follow @TracyStaton

@EricPFierce: Bill that would have paid drug disposal costs in California out of pharma's pocket left in the recycle bin. Article | Follow @EricPFierce

@CarlyHFierce: Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delay. More | Follow @CarlyHFierce

> Actavis ($ACT) said its president of global R&D, G. Frederick Wilkinson, will leave the company to take the helm of generics rival Impax Laboratories ($IPXL). Release

> GlaxoSmithKline's ($GSK) chronic obstructive pulmonary disease treatment Incruse Ellipta won approval in Canada. Release

> A Chicago jury awarded $14 million to a woman who sued her doctor over a stroke she suffered after taking Bayer's birth control pill Yasmin. Report

> Merck Serono's new president and CEO, Belén Garijo, has been appointed as an independent director of L'Oréal. Report

> Drug side-effects data company AdverseEvents closed a $2 million Series A funding round, aiming to expand its sales force and analyst teams, and step up marketing efforts. Release

> Cubist Pharma pulled one lot of its antibiotic Cubicin after a customer reported glass particles in a vial from that lot. Report

Medical Device News

@FierceMedDev: OPKO Health to buy Israeli inhaler developer Inspiro Medical for undisclosed price. News | Follow @FierceMedDev

@VarunSaxena2: Report: Pfizer pitches $101B megamerger to struggling AstraZeneca - FierceBiotech. More from FierceBiotech | Follow @VarunSaxena2

@EmilyWFierce: Wearable data glove that translates motion into sound could mean big things for the American deaf community. Story | Follow @EmilyWFierce

@MichaelGFierce: MIT team delivers three ovarian cancer drugs with one particle. Article from FierceDrugDelivery | Follow @MichaelGFierce

> Medtronic, Edwards need heart-to-heart over post-injunction access. More

> EndoStim bags a CE mark for MRI-safe reflux device. Item

> Advanced Cardiac Therapeutics raises $7M-plus for ablation catheter technology. Story

Biotech News

@FierceBiotech: Former Creighton professor named chief medical officer at 23andMe. Roundup | Follow @FierceBiotech

@JohnCFierce: I added the top 5 rounds from Q1 in my biotech VC story. And not a one of the biotechs is in the Boston area. Story | Follow @JohnCFierce

@DamianFierce: Here's some NYTimes background on the procedure FDA's warning about (with a remarkably NYTish headline): Article (sub. req.)| Follow @DamianFierce

@EmilyMFierce: New MRSA superbug emerges in Brazilian patient. Story | Follow @EmilyMFierce

> Sarepta rockets up after mapping a shortcut to the FDA with DMD hopeful eteplirsen. Story

> Zafgen tees up an $86M IPO for eye-catching obesity drug. More

> Say what? Pfizer's $101B buyout pitch to AstraZeneca sparks a megadebate. News

CRO News

> Certara buys Synchrogenix with its eye on regulatory writing. Story

> InVentiv signs up to get IntelliCell's regenerative drug into the clinic. More

> AMRI plans to shutter an R&D shop to save cash. Article

> Quintiles taps OmniComm for early-stage data management. News

> WuXi poaches an AstraZeneca exec to amp up Chinese R&D. Report

Biotech IT News

> U.K. and Canadian governments back bioinformatics, omics research projects. More

> BlackBerry plans healthcare-focused smartphone after making eClinical investment. Story

> Europe puts data management at the heart of $4B drug innovation drive. Article

> Pfizer, PhRMA and others pick holes in FDA social media guidance. News

> Google adds UCSF geneticist to Calico's roster. Report

And Finally... Some generic drugs have had eye-popping price spikes. Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.